Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel– cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 4125-4140

  Ye, Jun ^a,b   Xia, Xuejun ^a,b   Dong, Wujun ^a,b   Hao, Huazhen ^a,b   Meng, Luhua ^a,b   Yang, Yanfang ^a,b   Wang, Renyun ^a,b   Lyu, Yuanfeng ^c   Liu, Yuling ^a,b  

^a State Key Laboratory of Bioactive Substance and Function of Natural Medicines   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Lipid emulsion; Low density lipoprotein; Paclitaxel; Triple negative breast cancers; Tumor targeting

Indexed keywords

LIPID EMULSION; LOW DENSITY LIPOPROTEIN RECEPTOR; PACLITAXEL; ANTINEOPLASTIC AGENT; CHOLESTEROL; EMULSION; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; EMULSION; MCF-7 CELL LINE; METABOLISM; PHARMACOKINETICS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHOLESTEROL; DRUG SCREENING ASSAYS, ANTITUMOR; EMULSIONS; FEMALE; HUMANS; LIPIDS; MCF-7 CELLS; MICE, INBRED BALB C; PACLITAXEL; RECEPTORS, LDL; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84985898262     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S113638     Document Type: Article

References (41)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
2. DeSantis CE, Fedewa SA, Sauer AG, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31-42.
3. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-1948.
4. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109(9):1721-1728.
5. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281.
6. De Laurentiis M, Cianniello D, Caputo R, et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev. 2010;36 Suppl 3:S80-S86.
7. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334.
8. Isakoff SJ. Triple negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010;16(1):53-61.
9. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9(1):29-33.
10. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer: deciphering the heterogeneity. Clin Cancer Res. 2014;20(4):782-790.
11. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm. 2007;328(1): 86-94.
12. Stranzl A, Schmidt H, Winkler R, Kostner GM. Low-density lipoprotein receptor mRNA in human breast cancer cells: influence by PKC modulators. Breast Cancer Res Treat. 1997;42(3):195-205.
13. Zhang B, Sun X, Mei H, et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 2013;34(36):9171-9182.
14. Rotheneder M, Kostner GM. Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines. Int J Cancer. 1989;43(5):875-879.
15. Antalis CJ, Arnold T, Rasool T, Lee B, Buhman KK, Siddiqui RA. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat. 2010;122(3):661-670.
16. Antalis CJ, Uchida A, Buhman KK, Siddiqui RA. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin Exp Metastasis. 2011; 28(8):733-741.
17. Kim JH, Kim Y, Bae KH, Park TG, Lee JH, Park K. Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles. Mol Pharm. 2015;12(4):1230-1241.
18. Reynolds L, Mulik RS, Wen X, Dilip A, Corbin IR. Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells. Nanomedicine (Lond). 2014;9(14):2123-2141.
19. Jain A, Jain K, Kesharwani P, Jain NK. Low density lipoproteins mediated nanoplatforms for cancer targeting. J Nanopart Res. 2013; 15(9):1888.
20. Lee JY, Kim JH, Bae KH, et al. Low-density lipoprotein-mimicking nanoparticles for tumor-targeted theranostic applications. Small. 2015;11(2):222-231.
21. Rodrigues DG, Covolan CC, Coradi ST, Barboza R, Maranhao RC. Use of a cholesterol-rich emulsion that binds to low-density lipoprotein receptors as a vehicle for paclitaxel. J Pharm Pharmacol. 2002;54(6): 765-772.
22. Rodrigues DG, Maria DA, Fernandes DC, et al. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother Pharmacol. 2005;55(6):565-576.
23. Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol. 2009;63(2):281-287.
24. Teixeira RS, Valduga CJ, Benvenutti LA, Schreier S, Maranhão RC. Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors. J Pharm Pharmacol. 2008;60(10):1287-1295.
25. Kretzer IF, Maria DA, Guido MC, Contente TC, Maranhao RC. Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice. Int J Nanomedicine. 2016; 11:885-904.
26. Xia XJ, Guo RF, Liu YL, et al. Formulation, characterization and hypersensitivity evaluation of an intravenous emulsion loaded with a paclitaxel-cholesterol complex. Chem Pharm Bull (Tokyo). 2011;59(3): 321-326.
27. Ye J, Liu Y, Xia X, et al. Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors. Oncol Rep. 2016;36(1):399-409.
28. Nagelkerke A, Bussink J, Sweep FC, Span PN. Generation of multicellular tumor spheroids of breast cancer cells: how to go three-dimensional. Anal Biochem. 2013;437(1):17-19.
29. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm. 2009;382(1-2):198-204.
30. Chiu YL, Ho YC, Chen YM, et al. The characteristics, cellular uptake and intracellular trafficking of nanoparticles made of hydrophobically-modified chitosan. J Control Release. 2010;146(1):152-159.
31. Zhu QL, Zhou Y, Guan M, et al. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy. Biomaterials. 2014;35(22): 5965-5976.
32. Huang H, Cruz W, Chen J, Zheng G. Learning from biology: synthetic lipoproteins for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(3):298-314.
33. Meng F, Asghar S, Xu Y, et al. Design and evaluation of lipoprotein resembling curcumin-encapsulated protein-free nanostructured lipid carrier for brain targeting. Int J Pharm. 2016;506(1-2):46-56.
34. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release. 2007;124(3):163-171.
35. Emami J, Rezazadeh M, Varshosaz J. Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: a detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. J Nanomater. 2012;2012:358782.
36. Kretzer IF, Maria DA, Maranhão RC. Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion. Cell Oncol (Dordr). 2012;35(6):451-460.
37. Zelenko Z, LeRoith D, Antoniou IM, Rajan L, Gallagher EJ. Silencing the LDLR in breast cancer cells leads to decreased growth of tumor xenografts in a mouse model of hyperlipidemia. Poster presented at: 2016 Endocrine Society Annual Meeting; April 1-4, 2016; Boston, MA.
38. Lei H, Hofferberth SC, Liu R, et al. Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids. J Thorac Cardiovasc Surg. 2015;149(5):1417-1425.
39. Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials. 2012;33(32):8167-8176.
40. Ivaturi S, Wooten CJ, Nguyen MD, Ness GC, Lopez D. Distribution of the LDL receptor within clathrin-coated pits and caveolae in rat and human liver. Biochem Biophys Res Commun. 2014;445(2):422-427.
41. Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev. 2013;65(1):121-138.